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Abstract
Background: Pulmonary arterial hypertension (PAH) is thought to be driven by dysfunction of pulmonary vascular
microendothelial cells (PMVEC). Most hereditary PAH is associated with BMPR2 mutations. However, the physiologic
and molecular consequences of expression of BMPR2 mutations in PMVEC are unknown.
Methods: In vivo experiments were performed on adult mice with conditional endothelial-specific expression of
the truncation mutation Bmpr2delx4+, with age-matched transactivator-only mice as controls. Phenotype was
assessed by RVSP, counts of muscularized vessels and proliferating cells, and staining for thromboses, inflammatory
cells, and apoptotic cells. The effects of BMPR2 knockdown in PMVEC by siRNA on rates of apoptosis were
assessed. Affymetrix expression arrays were performed on PMVEC isolated and cultured from triple transgenic mice
carrying the immortomouse gene, a transactivator, and either control, Bmpr2delx4+ or Bmpr2R899X mutation.
Results: Transgenic mice showed increased RVSP and corresponding muscularization of small vessels, with
histologic alterations including thrombosis, increased inflammatory cells, increased proliferating cells, and a
moderate increase in apoptotic cells. Expression arrays showed alterations in specific pathways consistent with the
histologic changes. Bmpr2delx4+ and Bmpr2R899X mutations resulted in very similar alterations in proliferation,
apoptosis, metabolism, and adhesion; Bmpr2delx4+ cells showed upregulation of platelet adhesion genes and
cytokines not seen in Bmpr2R899X PMVEC. Bmpr2 mutation in PMVEC does not cause a loss of differentiation
markers as was seen with Bmpr2 mutation in smooth muscle cells.
Conclusions: Bmpr2 mutation in PMVEC in vivo may drive PAH through multiple, potentially independent,
downstream mechanisms, including proliferation, apoptosis, inflammation, and thrombosis.
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Background
Pulmonary arterial hypertension (PAH) is a lethal disor-
der characterized by pulmonary vasoconstriction and
vascular remodeling, leading to progressively worsening
right ventricular strain, and eventual right heart failure
[1]. Early molecular and physiologic events in the devel-
opment of the idiopathic form of PAH (IPAH) are not
known. However, in most theories of etiology, the pul-
monary microvascular endothelial cell (PMVEC) plays a
central role, either because of aberrant signaling to the
smooth muscle[2], excess proliferation which fills in
vessels[3], or excess apoptosis which causes vessels to
drop out[4].
The familial form of PAH is usually caused by muta-
tions in the type 2 receptor for the bone morphogenetic
protein signaling pathway, BMPR2[5,6], and there is
substantial evidence that suppression of the BMP path-
way is involved in all idiopathic PAH[7]. However,
detailed effects of BMPR2 mutation in endothelium,
either in vivo or in vitro, are not known.
BMPR2 signals through multiple downstream pathways
[8]. In canonical signaling, when a dimer of BMPR2
receptors forms a complex with a dimer of type 1 recep-
tors in the presence of ligand, the type 2 receptors phos-
phorylate and thus activate the type I receptor, allowing
the type 1 receptor to phosphorylate SMAD transcription
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factors 1, 5, or 8. The SMAD transcription factor
complexes with SMAD4, and enters the nucleus to tran-
scribe targets. However, BMPR2 also possesses a long
cytoplasmic tail, well conserved by evolution but found
in no other TGFb superfamily receptor. This tail domain
is not required for SMAD signaling[9], and signals
through other, currently poorly understood, pathways
[10,11]. Mutations in human patients can fall anywhere
in the gene[12]. Determining the common molecular
consequences of SMAD dependent and cytoplasmic tail
dependent signaling is thus important to determining
how BMPR2 mutation predisposes to disease.
We have previously reported physiologic and molecu-
lar consequences in smooth muscle of inducible trans-
genic overexpression of Bmpr2 mutants with defects in
SMAD-dependent (and cytoplasmic tail-dependent
(Bmpr2R899X) signaling[9,13,14]. These transgenic mice
rely on the fact that the Bmpr2 receptor works as a
dimer; thus, overexpression of a mutant protein inhibits
expression of the native protein in two ways - by acting
as a decoy receptor, and by binding native receptor into
a nonfunctional complex.
The goal of this study is to complete a first description
of the physiologic and molecular consequences of the dif-
ferent classes of Bmpr2 mutation in endothelium. Yelle et
al have already reported physiologic consequences of our
Bmpr2R899X mutant under an endothelial promoter[15].
In this report we thus express our doxyycline-inducible
Bmpr2delx4+ mutant in adult mice under the control of a
previously published Tie2 promoter[16-18] and perform
hemodynamic and histologic examination of conse-
quences. To determine molecular consequences, we cul-
tured PMVEC from control, Bmpr2R899X, and Bmpr2delx4
mice, and performed expression analyses using Affyme-
trix arrays. We found that Tie2-rtTA x TetO7-Bmpr2
delx4
mice developed variably elevated RVSP, associated with
increased muscularization particularly of small arteries,
increased proliferation, infiltration of a variety of inflam-
matory cell types, increased thrombosis, and increased
apoptosis. Expression analysis found that Bmpr2delx4 and
Bmpr2R899X mutations caused very similar changes in
proliferation, apoptosis, adhesion, and metabolism, but
were quite different in their effect on inflammatory and
thrombotic genes.
Methods
Generation of Tie2-rtTA x TetO7-Bmpr2
delx4+ mice
Both transgenes used for this double-transgenic mice
have been independently previously published. The Tie2-
rtTA mouse was originally generated for study of neovas-
cular retinopathy, and was shown to be endothelial speci-
fic in that context[16-18]. The TetO7-Bmpr2
delx4+ mice
were first described and validated crossed to a smooth
muscle-specific SM22-rtTA second transgene[14]. Both
mice were on an Fvb/n strain background. Double trans-
genic mice are doxycycline inducible; they express very
little transgene until fed doxycycline, with expression
levels in whole lung roughly equivalent to expression in
the lungs of our previously published SM22-rtTA x
TetO7-Bmpr2
delx4+ model[14].
Mouse Phenotyping Protocol
Mice were given Avertin (500 mg/kg IP) to induce a
surgical plane of anesthesia. The animals were then
shaved to expose the surgical area. Mice were placed on
a heated surgical table (Harvard Apparatus 872/1, 872/
H, Holliston, MA) and secured with surgical tape. Sys-
temic blood pressure and pulse was measured via a tail
cuff and pulse transducer run through a PowerLab
NIBP Controller (ADInstruments, Colorado Springs,
CO). The surgical site was viewed using a Zeiss OpMi 1
surgical microscope. An incision of approximately 1
inch in length was made extending from the animal’s
chin down to the right armpit. The thyroid gland was
then blunt dissected upwards to expose the underlying
tissue and the right jugular vein. The jugular vein was
then separated from surrounding tissue using dissecting
forceps until the body of the vessel was completely free
from adherent tissues. The cranial end of the jugular
was tied off completely and a loose tie was then made
at the caudal end of the exposed jugular using 4-0
braided silk suture. 4” Micro-dissecting scissors were
then used to make a small incision in the medial aspect
of the right jugular vein. A Millar 1.4 French pressure/
volume micro-tip catheter transducer (SPR-839, Millar
Instruments, Houston, TX) connected to a PowerLab/8S
(ADInstruments) was then inserted through the incision
and gently threaded down into the right ventricle.
Proper placement within the ventricle was determined
through observation of the pressure volume loop
obtained from the catheter. The loose caudal suture was
then tightened to secure the catheter in place. Once the
catheter is properly placed, data was collected using
Chart 5 for Windows (ADInstruments). Once blood
pressure and volume data was collected, the caudal
suture was re-loosened and the catheter removed for tis-
sue inflation. 100U of heparin was then injected through
the jugular incision to prevent clotting. The suture was
then re-tightened to prevent bleeding. The animals were
then removed from the surgical table to a dissecting
area. All animal procedures were approved by the
UCHSC animal care and use committee (IACUC).
Mouse tissue collection and morphometry
After checking for insensitivity to toe-pinch, a parame-
dian sternotomy was performed, lungs were flushed
with saline injected through the RV, the right lung was
tied off, and the left lung was inflated using low-melt
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agarose injected through the trachea. The left lung was
removed and fixed in 10% formalin and paraffin
embedded. The right lung was flash-frozen in liquid
nitrogen. Hearts were collected for weighing to deter-
mine right ventricular muscularization. Lung sections
were stained for smooth muscle actin (SMA), counter-
stained with hematoxylin, and imaged using a Zeiss
Axioscop 2 microscope. Twelve 20x microscopic fields
were collected from each animal from which counts of
fully or partially (less than 50%) muscularized vessels
and vessel diameter were collected.
Immunoflourescence and Carstair’s Stain
Immunofluorescence was done as previously described
using the following antibodies and dilutions. Monoclo-
nal anti-alpha smooth muscle actin antibody was pur-
chased from Sigma (St. Louis, MO) and used at a
dilution of 1:1000. Rabbit polyclonal anti-smooth muscle
actin was purchased from Abcam (Cambridge, MA) and
used at a dilution of 1:250. Rabbit polyclonal anti CD45
was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA) and used at 1:100. Rabbit polyclonal CD3
epsilon was purchased from Abcam (Cambridge, MA)
and used at a dilution of 1;200. Mac-3 antibody was
purchased from BD Pharmingen (San Jose, CA) and
used at a dilution of 1:200. Tissues processed for immu-
nofluorescence were rinsed and placed in either Alexa
Fluor 488 or 594 (Invitrogen, Carlsbad, CA) secondary
antibody at a 1:1000 dilution for 1 hour at room tem-
perature in the dark. Slides were then rinsed with PBS
and coverslipped with Vectashield with DAPI (Vector
Laboratories, Burlingame, CA). All staining was evalu-
ated and digital images acquired using a Zeiss Axioskop
2 equipped with an AxioCam (Carl Zeiss Microscopy,
Jena Germany). Carstairs’ stain[19] for fibrin and plate-
lets was done by IHC tech (LLC12635 Montview Blvd.
Ste. 215 Aurora CO, 80045) Briefly, deparaffinized slides
were incubated 5 minutes in ferric aluminum, rinsed,
stained with Mayer’s hematoxylin 5 minutes, rinsed,
stained in picric acid- orange G solution for 30 minutes,
rinsed, differentiated with 1% phosphotungstic acid,
rinsed and stained with aniline blue solution for 1 hr
and rinsed before mounting. This is a modification of
picro-Mallory staining, resulting in orange to red fibrin,
gray-blue platelets, bright blue collagen, red muscle, and
red, green, or yellow red blood cells.
Cell culture and siRNA
Murine pulmonary microvascular endothelial cells
(MVECs) were isolated by collagenase digest of whole
lung tissue and selected by cytometry using PECAM-1.
The isolated cells were grown to ~60% confluency on
10 cm cell culture dishes in Endothelial Growth Media
2 (EGM2) containing 5% serum. Following VE-Cadherin
and diLDL staining to confirm EC phenotype, transfec-
tions were done at passage 3 using 100 nM scrambled
siRNA control (Qiagen, Valencia, CA) or siRNA to
BMPR2 (Ambion). Lipofectamine and Plus reagents
(Invitrogen, Carlsbad, CA) were mixed with Optimem
media (Invitrogen) and siRNA as per manufacturer’s
instructions. EGM2 media was replaced with Optimem
before lipid-RNA complexes were added to the cells and
incubated for 2 hours at 37°C. A volume of EGM2
media containing 10% serum equal to that already on
the plate was then added to the existing transfection
media and the cells were incubated for and additional
24-48 hrs. Cells were subsequently harvested using the
PARIS kit from Ambion (Austin, TX). To extract the
BMPR2 from the membrane, SDS was added to a final
concentration of 6%. Equal amounts of protein deter-
mined using BCA protein assay (Pierce, Rockford, IL)
was loaded onto a 10% polyacrylamide gel with 10% gly-
cerol and transferred to Hybond-P membrane (Amer-
sham, Piscataway, NJ). BMPR2 is detected with a mouse
monoclonal antibody diluted 1:150 (BD Transduction
Laboratories, San Jose, CA) and visualized by chemilu-
minescence (ECL, Amersham, Piscataway, NJ).
Apoptosis - Tissue
The fluorescein FragEL DNA fragmentation detection
kit (Calbiochem, San Diego, CA) was used to look at
fragmented DNA signifying apoptosis. The manufac-
turer’s protocol was followed. Briefly, paraffin embedded
lung tissue from Tie2- BMPR2delx4+ and control mice
were cut, put onto slides and deparaffinized as described
above. Fragmented DNA was labeled using terminal
deoxynucleotidyl transferase which binds to exposed
3’-hydroxyl ends left after fragmentation of DNA in
response to apoptotic signals and catalyzes the addition
of fluorescein-labeled and unlabeled deoxynucleotides
allowing for visualization.
Apoptosis - Cells
Plates (60 mm) were seeded with 3 × 105 mouse pul-
monary microvascular endothelial cells in Minimum
Essential-alpha (MEM-a) media (Invitrogen, Carlsbad,
CA) supplemented with 20% FBS and incubated over-
night. BMPR2 siRNA or scrambled siRNA (100 nM,
Ambion) was transfected using Lipofectamine and Plus
reagent (Invitrogen, Carlsbad, CA), cells were recovered
with complete media at 2 h. At 72 h cells were trypsi-
nized, washed with ice-cold PBS and resuspended in 1
ml of PBS. Apoptotic cells were labeled with YO-PRO-1,
Vybrant Apoptosis Assay (Invitrogen, Carlsbad, CA)
which stains apoptotic cells green fluorescent while
necrotic cells stain red fluorescent with propidium
iodide separating early apoptosis and necrosis using flow
cytometry. To prevent apoptosis through the BMPR2
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pathway, cells were seeded as described above. After
overnight incubation, cells were washed with PBS and
media replaced with MEM-a without FBS. At 24 h, 150
ng/ml BMP-2 (R&D systems, Minneapolis MN) was
added and at 72 h cells were trypsinized, washed with
ice-cold PBS and resuspended in 1 ml of PBS. Apoptotic
cells were labeled with YO-PRO-1 (Vybrant Apoptosis
Assay, Molecular Probes) and analyzed by flow
cytometry.
Generation of murine PMVEC
Immortomouse X Rosa26-rtTA2 X TetO7-Bmpr2
R899X
or Immortomouse X Rosa26-rtTA2 X TetO7-Bmpr2
delx4
+ triple transgenic mice (Immorto-Bmpr2R899X) were
bred with transgenes verified by PCR genotyping of tail
DNA. The immortomouse contains a transgenic inser-
tion of the SV40 large T antigen, tsA58, under control
of an interferon-inducible promoter[20]. When cells are
grown at 33°C and interferon is added, the transgene is
activated and the cells are immortalized and proliferate
freely; at 37°C, this transgene is inert. The immorto-
mouse therefore produces cells which proliferate as
though they were immortalized at 33°C, but revert to a
more normal phenotype when cultured at 37°C.
Immorto-Bmpr2R899X PMVEC were collected from adult
mice as previously described[21], and verified by stain-
ing for endothelial markers VWF, PECAM, and VE-
Cadherin.
Affymetrix arrays
Mouse Gene 1.0 microarrays (Affymetrix, Foster City,
CA) were performed on pooled RNA from three plates
each. Array results were submitted to the NCBI gene
expression and hybridization array data repository
(GEO, http://www.ncbi.nlm.nih.gov/geo/), accession
number pending. Arrays were analyzed using a combi-
nation of Affymetrix Expression Console, comparisons
within Microsoft Excel, and Webgestalt for gene ontol-
ogy groupings[22].
Statistics
Statistical analysis was performed with Statview 5.0 (SAS
Institute, Cary NC). Specific tests used are listed in fig-
ure legends, with p < .05 considered significant.
Results
Tie2-Bmpr2delx4+ mice have increased RVSP,
muscularization of vessels, and cellular proliferation
Adult Tie2-rtTA x TetO7- Bmpr2
delx4+ (Tie2-Bmpr2delx4
+ for brevity) mice had the mutant Bmpr2 transgene
activated in endothelium for 12 weeks through 1 g/kg
doxycycline in chow; transactivator-only controls were
similarly treated. Weight in both sexes was increased by
about 20% (p < .01 by two-way ANOVA) in Tie2-
Bmpr2delx4+ mice compared to age- and sex- matched
controls, as has been seen in our previous Bmpr2 mod-
els[9,14]. Tie2-Bmpr2delx4+ mice also seemed to have a
much higher frequency of fighting injuries, although we
are not currently equipped to formally assess behavioral
changes. Hemodynamic phenotype was evaluated by
closed-chested cardiac catheterization, systemic pressure
measurements by tail cuff, and muscularization of ves-
sels was assessed by immunohistochemistry. Systemic
pressures were normal (not shown), in the range of 90-
120 mm Hg in both transactivator-only control and
Tie2-Bmpr2delx4+ mice. Closed-chested right ventricular
systolic pressure (RVSP) was increased from 27 mmHg
to 40 mmHg on average, and from 27 mm Hg to 35
mm Hg at the median (Figure 1A), significant at p =
.003 by t-test with unequal variances, and p = .007 by
Kruskal-Wallis (non-parametric) test.
Tissues were collected from additional groups of Tie2-
Bmpr2delx4+ with transgene activated 2.5 and 8 weeks to
allow more complete analysis of histologic changes.
There was an increase in muscularization of very small
(<25 mm) vessels by 2.5 weeks, and an increase in both
small and mid-sized vessels (25-50 mm) by 8 weeks; lar-
ger vessels never had a statistically significant increase
in muscularization (Figure 1B-F).
Tie2-Bmpr2delx4+ mice showed about a threefold
increase in proliferating cells in pulmonary vasculature,
by counts of proliferating cell nuclear antigen (PCNA)
positive cells (Figure 2). Increased PCNA staining was
found in vessels of all sizes at 8 and 12 weeks.
Tie2-Bmpr2delx4+ mice have increased pulmonary
inflammatory cells and thromboses
Tie2-Bmpr2delx4+ mice had a large increase in the num-
ber of inflammatory cells found throughout the lung, as
assessed by immunofluorescence for the pan-leukocyte
marker CD45 (Figure 3A,B). This included an increase
in both CD68+ macrophages (Figure 3C,D) and CD3+
T-cells (Figure 3E,F). Aside from a small number of
alveolar macrophages, inflammatory cells are rarely
found in control mouse lungs. Human PAH is charac-
terized by massive perivascular inflammation, even
around relatively normal vessels (Figure 3G). While we
did see occasional perivascular inflammation, primarily
of CD3+ cells, it was not as common or dramatic as in
human PAH (Additional File 1, Figure S1).
Tie2-Bmpr2delx4+ mice also showed large numbers of
thrombi in vessels (Figure 4). We do not believe that
these could be an artifact of collection: our standard
protocol for lung harvest includes pre-harvest perfusion
with heparin and phosphate buffered saline, which gen-
erally clears the vessels; however, even when it does not,
the result is vessels with loose collections of red blood
cells, not a mature clot. Clots could be found in vessels
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of all sizes, from very small pre-capillary vessels (Figure
4A,B) to the large arteries adjacent to airways (Figure
4C,D).The frequency was variable from mouse to mouse
and even across areas of lung in the same mouse,
although there were areas in which most vessels were
occluded (Additional File 2, Figure S2A). This inconsis-
tency matches findings in human PAH, in which the
same mutation can result in frequent thrombotic lesions
in some patients, but not in others [23-25].
Thrombosis and perivascular inflammation could be
found together (Additional File 2, Figure S2B), but this
was uncommon.
Loss of endothelial BMP signaling results in apoptosis in
vivo and in culture
Studies to analyze the effects of defective Bmpr2 on apop-
tosis in vivo and in vitro were conducted. In vivo, apoptotic
cells were identified by detecting fragmented DNA in tis-
sue obtained from mice treated for 12 weeks with doxycy-
cline. Apoptosis is shown localized to the endothelium of
vessels (Figure 5A). However, from histology, it was diffi-
cult to determine how widespread the problem was. In
vitro, mouse cultured endothelial cells responded to inhi-
bition of Bmpr2 by siRNA with substantially increased
apoptosis (Figure 5B) as previously reported in human
ECs[26]. In addition, BMP2 protects ECs from apoptosis
under serum starved conditions (Figure 5C).
Molecular consequences of Bmpr2delx4+ and Bmpr2R899X
mutations in PMVEC
PMVEC were cultured from double and triple trans-
genic mice, expressing the Immortomouse transgene
Figure 1 RVSP and muscularization are increased in Tie2-
Bmpr2delx4+ mice. (A) Scatter plot showing RV systolic pressures
from 11 Tie2- Bmpr2delx4+ mice and 6 control mice after 12 weeks’
doxycycline. (B) Graph of muscularization of vessels visualized by
actin staining showing a statistically significant increase in vessels
under 25 μm compared to control at all time points, and an increase
in muscularized vessels 25-50 μm compared to controls at the 8 and
12 week time points (p < .0001 by ANOVA with post-hoc t-test).
There is never a statistically significant increase in muscularization in
vessels over 50 μm. (C-F) Representative actin staining in control (C),
2.5 week (D), 8 week (E), and 12 week (F) time points, showing a
progressive increase in small muscularized vessels.
Figure 2 (A) Quantification of nuclei with PCNA staining
substantially greater than the median by histology indicates
strong increases in proliferation in Tie2- Bmpr2delx4+ mouse
lung (p < .0001 by ANOVA with post-hoc t-test; no significant
difference between 8 and 12 week time points) (B)
Representative fields demonstrate that increased PCNA
staining is found in vessels of all sizes.
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[20], the Rosa26-rtTA2 transgene[27], and either no
additional transgenes (control PMVEC), the TetO7-
Bmpr2R899X, or the TetO7-Bmpr2
delx4+ transgene. The
immortomouse transgene was added because it is other-
wise impractical to collect enough PMVEC from mice
to perform experiments. Affymetrix Mouse Gene 1.0
microarrays were used to determine molecular conse-
quences of Bmpr2delx4+ and Bmpr2R899X mutations in
PMVEC. Two arrays were run for each cell type, with
RNA for each array consisting of a pool of three inde-
pendently grown plates (total of six arrays).
Using a requirement of a minimum of a 1.4x change,
a minimum expression intensity of the higher of the
pair of at least 128 (arbitrary Affymetrix units), and
average expression values separated by more than the
sum of their standard deviations (which equates to
roughly a p < .05 for difference), we found 840 unique
genes with gene ontology information differentially
expressed in Bmpr2delx4+ compared to controls (Addi-
tional File 3, Table S1), and 1692 differentially expressed
in Bmpr2R899X mutants compared to controls (Addi-
tional File 4, Table S2).
Distribution of gene ontology groups in these genes is
nearly identical between Bmpr2delx4+ and Bmpr2R899X
PMVEC (Figure 6), consisting of metabolic, develop-
mental, cytoskeletal, stimulus-response, proliferation,
and apoptosis-related genes. This distribution of gene
ontology groups is very similar to those seen as a com-
mon consequence of different categories of BMPR2
mutation in cultured vascular smooth muscle cells[27],
with differences discussed below. In most ontology
groups, direction of changes are also concordant
between mutation types; the exceptions are inflamma-
tory and thrombotic genes, as discussed below.
We also found that within most specific pathways, the
changes caused by expression of Bmpr2delx4+ and
Bmpr2R899X in PMVEC were congruent. For apoptosis,
we found common upregulation of Bmp target Msx1,
known to drive apoptosis[28] (Figure 7A); overexpres-
sion of Msx1 is associated with capillary dropout[29].
Examples of other upregulated apoptosis-related genes
include Lhx2, which complexes with Msx1[30], Death
Associated Protein 1(Dap), and endothelial apoptosis
gene Bnip3[31], while apoptosis inhibitor Bax is downre-
gulated. We also found congruent alterations in multiple
proliferation-related genes (Figure 7B). Examples include
an increase in TGFbeta target SerpinE1 and in
TGFbeta-mediated proliferation gene Cyclin B2(Ccnb2),
and downregulation of Sestrin 2(Sesn2), key p53 target
PTPRV[32], and prostaglandin e synthase (Ptges).
Bmpr2delx4+ and Bmpr2R899X also showed matching
alterations in adhesion related genes (Figure 7C), includ-
ing for example downregulation of tight junction protein
Claudin 10a (Cldn10a), intercellular adhesion molecule
Cadm2, cell-cell adhesion molecule Itga1, and Vav3, a
key regulator of Rho family GTPases especially as
related to adhesion[33]. Finally, in metabolism (Figure
7D) we found concordant upregulation of oxidative
Figure 3 Increased inflammation in Tie2-Bmpr2delx4+ mouse lung compared to Tie2-rtTA only. Blue is DAPI nuclear stain; red corresponds
to pan-leukocyte marker CD45 (A,B), macrophage marker CD68 (C,D), or T-cell marker CD3 (E,F). In all cases, there are substantially more
inflammatory cells in representative fields from Tie2-Bmpr2delx4+ mouse lung than from control Tie2-rtTA only mouse lung. In contrast to this
pattern, end-stage human lung is characterized by massive perivascular inflammation (G) which can be seen in Tie2-Bmpr2delx4+ mice (Additional
Figure 1), but is not typical. Human lungs were prepared with Carstairs’ Stain.
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stress-response genes such as Gfpt2[34] and glycolysis
related genes such as Pgk1[35], with downregulation of
gluconeogenesis gene Eno2[36], and diacylglycerol
kinases Dgka and Dgkh, important in fatty acid metabo-
lism and insulin resistance[37].
In contrast, expression of Bmpr2delx4+ and Bmpr2R899X
mutations in PMVEC had very different effects on
inflammatory and thrombotic genes. Bmpr2delx4+ muta-
tion resulted in induction of multiple cytokines not
upregulated in Bmpr2R899X (Figure 7E). There were
many of these, but examples upregulated only in
Bmpr2delx4+ include the angiogenic chemokine Cxcl12
[38], the interleukin 27 receptor Il27ra, and the inflam-
matory cell adhesion molecule CD24a. Some inflamma-
tory genes were changed only in Bmpr2R899X, including
downregulation of MAP kinase p38δ (Mapk13) and
upregulation of the TH1 inducer interleukin 18 (Il18).
We also tested expression of interleukin 6, which we
had previously found to be regulated by Bmpr2delx4+
mutation in smooth muscle; we found it upregulated in
Bmpr2delx4+ mutant PMVEC, but not in Bmpr2R899X
(Additional File 5, Figure S3).
Effects of the two mutations were also very different in
thrombosis related genes (Figure 7F), with increases in
prothrombotic genes in Bmpr2delx4+ but not Bmpr2R899X;
examples include 4x increases in platelet/endothelial cell
adhesion molecule (PECAM1) and platelet chemokine
ligand Ccl5, a 28x increase in platelet adhesion molecule
selectin P (Selp), and an 18x increase in Entpd1, a
nucleotidase involved in response to thrombosis[39]. In
contrast, the anticoagulant thrombomodulin (Thbd) is
downregulated, but only in Bmpr2delx4+.
It is also worth noting a set of changes we did not see.
When we expressed Bmpr2 mutations in smooth mus-
cle, either in vivo or in vitro, expression of the
Bmpr2delx4+ mutation resulted in a broad loss of smooth
Figure 4 Tie2-Bmpr2delx4+ mouse lung has strongly increased frequency of thromboses in both small (A) and large (C) vessels. We
have never seen these in control lungs (B and D for comparison). Lungs were prepared with Carstairs’ stain as described in the methods section
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muscle markers[13,27]. It was clear from these data that
maintenance of SMAD signaling was required for
smooth muscle differentiation. Bmpr2 mutation did not
cause a broad loss of endothelial markers in PMVEC.
Table 1 shows a list of average expression of 14
endothelial markers; 7 are not substantially changed by
either mutation, and only one, vascular cell adhesion
molecule 1 (Vcam1) is consistently changed in both (it
is upregulated in both).
Figure 5 Bmpr2delx4+ mutation predisposes to increased
PMVEC apoptosis. (A) Immunofluorescence of fragmented DNA
labeled with fluorescein; red arrows point to positive nuclei (B)
PMVEC from control animals show increased apoptosis when
inhibited with siRNA directed to BMPR2 * = p < .05 by ANOVA. (C)
Representative scatter plots indicating exogenous BMP2 reduces
apoptosis in serum starved condition.
Figure 6 Gene ontology classification of genes dysregulated in
PMVEC cultured from BMPR2delx4+ mice (top) or Bmpr2R899X
mice (bottom) indicates very similar patterns of gene
dysregulation between mutation types. Angular width of
sections corresponds to proportion of genes within that ontology
group. Outer labels correspond to top-level gene ontology groups:
inner circle corresponds to more detailed gene ontology
classification, all from the biological process tree. Most genes fall
into more than one lower-level category, and so lower-level
categories selected are meant to be representative, but are
somewhat arbitrary. Full GO listing is included in Supplemental
Tables 1 and 2.
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Discussion
This study analyzed the physiologic and molecular
effects of Bmpr2 mutation in endothelium. We found
that most Tie2-Bmpr2delx4+ mice developed elevated
RVSP, although with large variability in degree. This
was associated with increased muscularization of small
arteries (Figure 1), an increase in proliferating cells
(Figure 2), inflammatory cells(Figure 3), thrombosis
(Figure 4), and apoptosis (Figure 5). Molecular changes
substantially matched the physiologic changes, with an
increase in gene ontology groups related to proliferation
(Figure 7B), apoptosis (Figure 7A), and thrombosis
(Figure 7F). The increase in inflammatory cells seen is
probably related both to the increase in cytokines
(Figure 7E, Additional File 5) and the decrease in cell-
cell adhesion genes (Figure 7C). BMPR2 has been pre-
viously shown to regulate endothelial barrier function in
the context of leukocyte transmigration[40]. We also
saw large scale alteration in metabolic genes, including
response to oxidative stress (Figure 6); this matches our
previous findings in smooth muscle and whole animals
[27]. Unlike expression of Bmpr2delx4+ mutation in
smooth muscle, expression in PMVEC did not cause
loss of differentiation markers. Overall, this is the first
report of the molecular effects of Bmpr2 mutation in
PMVEC, with results consistent with both our current
physiology and our previous findings.
Physiologic results from this mouse were similar to
results from an endothelial-specific BMPR2 knockout
mouse described by Hong et al[41], despite having very
different methods of generation. The only difference was
higher penetrance in our model (~80% as opposed to
~30%). Histologic details such as thromboses and perivas-
cular inflammatory cells and levels of increased proliferat-
ing cells were all almost identical between the models,
which strongly increases confidence that both models
accurately represent the consequences of complete sup-
pression of signaling through BMPR2 in the endothelium.
Both of these models are quite different in histologic
detail than expression of a different Bmpr2 mutation,
Bmpr2R899X, in endothelium[15]. Endothelial expression
of Bmpr2R899X, which retains intact Smad signaling[9],
results in vascular pruning and increased RVSP, but with-
out the obvious increase in thromboses. This also
matches our molecular data; increases in thrombotic
pathways were not seen in PMVEC with Bmpr2R899X
mutation (Figure 7F). Our molecular results imply that
neither increased thrombosis nor increased inflammation
are required for the development of Bmpr2-mediated
PAH, although obviously both could exacerbate disease.
Figure 7 Scatter plots indicating changes in illustrative genes
from different gene ontology groups in Bmpr2delx4+ (black
circles) or Bmpr2R899X (grey diamonds) PMVEC. In each plot, the
y-axis indicates fold change compared to control PMVEC on a log2
scale. Points falling on the 1x line are thus identical to controls;
those above are upregulated, and those below are downregulated.
Error bars indicate standard deviation in replicates; if they are
invisible, they are smaller than the symbol (experimental replicates
were very similar). Bmpr2delx4+ and Bmpr2R899X PMVEC had very
similar changes in apoptosis(A), proliferation (B), adhesion (C), and
metabolic (D) genes, but divergent changes in inflammatory (E) and
thrombotic (F) genes.
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Broadly, we believe that the sum of the data to date
suggests that the normal role of BMPR2 in the adult
pulmonary vasculature is as a master switch mediating
injury response. After injury, suppression of BMPR2
signaling through its cytoplasmic tail results in a
decrease in cell-cell adhesion to improve migration
and leukocyte recruitment, a metabolic shift towards
glycolysis to support production of proteins and lipids
needed for proliferation, and an increase in propensity
for both proliferation and apoptosis to support tissue
remodeling and angiogenesis or angeogenic repair.
Suppression of BMPR2 signaling through SMAD
results in an increase in thrombosis and an increase in
expression of cytokines, and in smooth muscle but not
endothelium, dedifferentiation. In those with intact
BMPR2, this naturally resolves as the injury is repaired.
In the case of BMPR2 mutation, these injury responses
can never be successfully resolved, leading to a patho-
logic continuation of the pro-thrombotic and pro-
proliferative pathways which would have been adaptive
in acute injury.
Decades ago, long before molecular origins of PAH
were known, there was controversy over whether the
initiating events in the disease involved inflammation,
proliferation, thrombosis, or vasoconstriction through
defective endothelial-smooth muscle communication[42].
The discovery of BMPR2 as the familial PAH gene had
promised a resolution to this controversy. However, the
current study, as well as its predecessors in the literature,
indicate that all of these are consequences of BMPR2
mutation alone, and our expression arrays suggest that
they may all be relatively direct consequences of BMPR2
mutation, not an in vivo cascade. Our study does not
address the issue of whether any are dispensable for the
development of PAH. However, since each of these indi-
vidually is capable of driving PAH in animal models[43],
it is possible that inflammation, proliferation, thrombosis,
and vasoconstriction in the context of pulmonary vascu-
lar injury can not be easily separated; it is not that one is
the cause and the other are bystanders, but rather they
are inextricably linked.
Conclusions
We present here a relatively comprehensive first look at
the physiologic and molecular consequences of Bmpr2
mutation. These data support an important role for
Bmpr2 signal in maintaining endothelial homeostasis,
and support our broad hypothesis that a normal role for
Bmpr2 is in injury response. Future studies will be
needed to determine the specific roles of and alterations
in pathways identified, including, p53-mediated prolif-
eration, MSX1-mediated apoptosis, a shift to glycolysis,
and a loss of cell-cell adhesion.
Additional material
Additional file 1: Figure S1. Examples of perivascular inflammation in
lungs from Tie2-Bmpr2delx4+ mice with transgene activated 12 weeks. All
images are from Tie2-Bmpr2delx4+ mice. Blue = DAPI nuclear stain, green
= actin, red = CD45 (left two images) or CD3 (right two images).
Roughly 15% of vessels had more than 1-2 associated leukocytes.
Additional file 2: Figure S2. (A) Some regions of some Tie2-Bmpr2delx4+
lungs had occlusion of most vessels present (red arrowheads). In general,
though, level of thrombosis was irregular from region to region within a
lung, and of variable degree between individual mice. (B) Some
thromboses (red arrowhead) had increased nearby inflammatory cells
(white arrowheads, red = CD45 staining), but this was not typical.
Additional file 3: Table S1. Genes differentially expressed in pulmonary
microvascular endothelial cells expressing the Bmpr2delx4+ mutationn as
compared to controls.
Table 1 Endothelial markers are not consistently changed by Bmpr2 mutation.
Control Delx4 R899X ANOVA Post Hoc (p < .05) Control
CD34 7135 0.5% 10325 5.3% 8001 0.1% <.01 Delx4 > Control 7135
Endoglin 2191 7.5% 5572 2.9% 316 4.6% <.0001 Delx4 > Control > R899X 2191
Endothelial-Specific Marker 1 103 4.8% 119 1.8% 122 0.3% <.05 Delx4 = R899X > Control 103
Flk1 (VEGF receptor 2) 1928 0.8% 1711 10.3% 684 3.6% <.01 Delx4 = Control > R899X 1928
Flt1 (VEGF receptor 1) 484 4.6% 312 5.4% 370 0.8% <.01 Control > R899X > Delx4 484
Icam2 190 3.3% 276 0.7% 201 0.4% <.001 Delx4 > Control = R899X 190
Multimerin 2 118 10.9% 127 0.4% 113 6.4% NS 118
Pecam1 114 14.6% 520 10.8% 118 3.3% <.01 Delx > Control = R899X 114
Selectin, endothelial cell 156 4.7% 167 10.2% 174 8.5% NS 156
Thrombomodulin 4855 3.5% 4669 3.9% 3013 6.8% <.01 Delx4 = Control > R899X 4855
Vcam1 2264 3.6% 8066 1.7% 3483 0.2% <.0001 Delx4 > R899X > Control 2264
VE-Cadherin 172 5.4% 230 0.1% 144 13.2% <.05 Delx4 > Control = R899X 172
Vegf-a 1308 4.1% 1176 6.1% 2283 11.7% <.05 R899X > Control = Delx4 1308
Von Willebrand factor 206 12.1% 231 5.5% 232 1.0% NS 206
Numbers are the average of two raw Affymetrix hybridization intensity numbers for each condition, with the standard deviation given as a percentage of that
number. ANOVA was performed for significant differences between groups, followed by a post-hoc t-test for which groups were different.
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Additional file 4: Table S2. Genes differentially expressed in pulmonary
microvascular endothelial cells expressing the Bmpr2R899X mutation as
compared to controls.
Additional file 5: Figure S3. Interleukin 6 expression is increased in
lungs from Bmpr2delx4+ mice with transgene activated 12 weeks (A) and
in PMVEC derived from Bmpr2delx4+, but not Bmpr2R899X, mice (B) by
quantitative RT-PCR. Error bars are standard deviation; normalization is to
HPRT as indicated on the vertical axis. For (A), each box is a separate
animal, p < .05 by unpaired t-test. For (B), each box is a separate plate, p
< .01 for delx4+ difference, p = NS for R899X difference by ANOVA with
post-hoc t-test.
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